Certara, a biosimulation software provider, has bought up Pinnacle 21 in a $310 million deal that adds a clinical data compliance solution to its offerings.

Pinnacle 21 provides software solutions that validate clinical trial data compliance with Clinical Data Interchange Standards Consortium (CDISC) standards. These standards are required by FDA and Japan’s Pharmaceuticals and Medical Devices Agency for drug submissions and preferred by China’s National Medical Products Administration.

Data standards are getting harder to meet as a result of the growing amount of data in clinical trials and the increasing use of wearables and other health technologies, according to Certara. Pinnacle 21’s validation software creates consistent, compliant and high-quality datasets that can lower the risk of regulatory delays and help accelerate drug development, the company said.